Laboratory and clinical studies on S-1108, a new oral cephem antibiotic

We performed bacteriological and clinical evaluations of S-1108, a new oral cephem antibiotic, with the following results : 1) Antimicrobial activity of S-1108 The minimum inhibitory concentrations (MICs) of S-1108 for total 302 clinicaly isolated strains, were determined and compaired with those of cefteram, cefotiam, cefixime, cefaclor and amoxicillin using the MIC-2000 system. S-1108 had broad antimicrobial activity against those clinical strains, except MRSA, Enterococcus faecalis, Serratia marcescens, Acinetobacter calcoaceticus and Pseudomonas aeruginosa. 2) Clinical efficacy S-1108, 100 mgx 3 (300 mg/day), was administered to 3 patients with chronic bronchitis for 7~14 days. Two patients with chronic bronchitis and a patients with bronchiectasis were treated with S-1108 in a dose of 150 mgx 3 (450 mg/day), for 7~14 days, and S-1108, 200mgx 3 (600 mg/day), was given to 3 patients with chronic bronchitis for 7~21 days. Clinical responses were good in 7 patients and fair in one patient. All strains of Haemophilus influenzae, Klebsiella pneumoniae, Streptococcus pneumoniae and Branhamella catarrhalis were eradicated, but one strain of S. pneumoniae was not eradicated. There was superinfection by H. influenzae and S. aureus in one case. No side effects were observed and no abnormally altered laboratory findings were observed.